Corticotrophin-releasing activity of desmopressin in Cushing's disease: Lack of correlation between in vivo and in vitro responsiveness

F. Pecori Giraldi, E. Marini, E. Torchiana, P. Mortini, A. Dubini, F. Cavagnini

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Desmopressin (DDAVP), an arginine vasopressin analogue, markedly stimulates ACTH secretion in patients with Cushing's disease, in contrast to its minimal effect in normal subjects. However, little is known about the mechanisms underlying this action and it appeared to be of interest to evaluate the effect of DDAVP on ACTH-secreting pituitary adenomas in vitro, in comparison with its effect in the same patients in vivo. Pituitary adenomas from 14 patients with Cushing's disease were incubated with DDAVP, corticotrophin-releasing hormone (CRH) and DDAVP together with vasopressin receptor antagonists or CRH. Incubation with DDAVP induced a modest dose-dependent increase in ACTH concentrations which appeared maximal at 10 nM. CRH stimulated ACTH to a greater extent compared with DDAVP and potentiated the effect of DDAVP alone. The DDAVP-induced ACTH increase appeared blunted by vasopressin V2 and V3 receptor antagonists. V3 receptor gene expression was detected by RT-PCR in all adenoma samples except for two which were not responsive to DDAVP in vitro but responsive to the peptide in vivo. Surprisingly, no difference in the in vitro ACTH secretory response was observed between in vivo DDAVP-responsive (ACTH peak> 150% baseline) and -unresponsive (ACTH peak<120% baseline) patients, suggesting that the pituitary adenoma is not the sole mediator of the ACTH-releasing effect of DDAVP. In conclusion, the marked stimulatory effect of DDAVP observed in patients with Cushing's disease appears to be mainly dependent on an extrapituitary action, possibly the inhibition of a corticotrophin release-inhibitory factor.

Original languageEnglish
Pages (from-to)373-379
Number of pages7
JournalJournal of Endocrinology
Volume177
Issue number3
DOIs
Publication statusPublished - Jun 1 2003

Fingerprint

Deamino Arginine Vasopressin
Pituitary ACTH Hypersecretion
Adrenocorticotropic Hormone
Corticotropin-Releasing Hormone
Vasopressin Receptors
Pituitary Neoplasms
In Vitro Techniques
ACTH-Secreting Pituitary Adenoma
Arginine Vasopressin
Adenoma

ASJC Scopus subject areas

  • Endocrinology

Cite this

Corticotrophin-releasing activity of desmopressin in Cushing's disease : Lack of correlation between in vivo and in vitro responsiveness. / Pecori Giraldi, F.; Marini, E.; Torchiana, E.; Mortini, P.; Dubini, A.; Cavagnini, F.

In: Journal of Endocrinology, Vol. 177, No. 3, 01.06.2003, p. 373-379.

Research output: Contribution to journalArticle

@article{0f7abc82ba584049a4becf24b1fd726b,
title = "Corticotrophin-releasing activity of desmopressin in Cushing's disease: Lack of correlation between in vivo and in vitro responsiveness",
abstract = "Desmopressin (DDAVP), an arginine vasopressin analogue, markedly stimulates ACTH secretion in patients with Cushing's disease, in contrast to its minimal effect in normal subjects. However, little is known about the mechanisms underlying this action and it appeared to be of interest to evaluate the effect of DDAVP on ACTH-secreting pituitary adenomas in vitro, in comparison with its effect in the same patients in vivo. Pituitary adenomas from 14 patients with Cushing's disease were incubated with DDAVP, corticotrophin-releasing hormone (CRH) and DDAVP together with vasopressin receptor antagonists or CRH. Incubation with DDAVP induced a modest dose-dependent increase in ACTH concentrations which appeared maximal at 10 nM. CRH stimulated ACTH to a greater extent compared with DDAVP and potentiated the effect of DDAVP alone. The DDAVP-induced ACTH increase appeared blunted by vasopressin V2 and V3 receptor antagonists. V3 receptor gene expression was detected by RT-PCR in all adenoma samples except for two which were not responsive to DDAVP in vitro but responsive to the peptide in vivo. Surprisingly, no difference in the in vitro ACTH secretory response was observed between in vivo DDAVP-responsive (ACTH peak> 150{\%} baseline) and -unresponsive (ACTH peak<120{\%} baseline) patients, suggesting that the pituitary adenoma is not the sole mediator of the ACTH-releasing effect of DDAVP. In conclusion, the marked stimulatory effect of DDAVP observed in patients with Cushing's disease appears to be mainly dependent on an extrapituitary action, possibly the inhibition of a corticotrophin release-inhibitory factor.",
author = "{Pecori Giraldi}, F. and E. Marini and E. Torchiana and P. Mortini and A. Dubini and F. Cavagnini",
year = "2003",
month = "6",
day = "1",
doi = "10.1677/joe.0.1770373",
language = "English",
volume = "177",
pages = "373--379",
journal = "Journal of Endocrinology",
issn = "0022-0795",
publisher = "BioScientifica Ltd.",
number = "3",

}

TY - JOUR

T1 - Corticotrophin-releasing activity of desmopressin in Cushing's disease

T2 - Lack of correlation between in vivo and in vitro responsiveness

AU - Pecori Giraldi, F.

AU - Marini, E.

AU - Torchiana, E.

AU - Mortini, P.

AU - Dubini, A.

AU - Cavagnini, F.

PY - 2003/6/1

Y1 - 2003/6/1

N2 - Desmopressin (DDAVP), an arginine vasopressin analogue, markedly stimulates ACTH secretion in patients with Cushing's disease, in contrast to its minimal effect in normal subjects. However, little is known about the mechanisms underlying this action and it appeared to be of interest to evaluate the effect of DDAVP on ACTH-secreting pituitary adenomas in vitro, in comparison with its effect in the same patients in vivo. Pituitary adenomas from 14 patients with Cushing's disease were incubated with DDAVP, corticotrophin-releasing hormone (CRH) and DDAVP together with vasopressin receptor antagonists or CRH. Incubation with DDAVP induced a modest dose-dependent increase in ACTH concentrations which appeared maximal at 10 nM. CRH stimulated ACTH to a greater extent compared with DDAVP and potentiated the effect of DDAVP alone. The DDAVP-induced ACTH increase appeared blunted by vasopressin V2 and V3 receptor antagonists. V3 receptor gene expression was detected by RT-PCR in all adenoma samples except for two which were not responsive to DDAVP in vitro but responsive to the peptide in vivo. Surprisingly, no difference in the in vitro ACTH secretory response was observed between in vivo DDAVP-responsive (ACTH peak> 150% baseline) and -unresponsive (ACTH peak<120% baseline) patients, suggesting that the pituitary adenoma is not the sole mediator of the ACTH-releasing effect of DDAVP. In conclusion, the marked stimulatory effect of DDAVP observed in patients with Cushing's disease appears to be mainly dependent on an extrapituitary action, possibly the inhibition of a corticotrophin release-inhibitory factor.

AB - Desmopressin (DDAVP), an arginine vasopressin analogue, markedly stimulates ACTH secretion in patients with Cushing's disease, in contrast to its minimal effect in normal subjects. However, little is known about the mechanisms underlying this action and it appeared to be of interest to evaluate the effect of DDAVP on ACTH-secreting pituitary adenomas in vitro, in comparison with its effect in the same patients in vivo. Pituitary adenomas from 14 patients with Cushing's disease were incubated with DDAVP, corticotrophin-releasing hormone (CRH) and DDAVP together with vasopressin receptor antagonists or CRH. Incubation with DDAVP induced a modest dose-dependent increase in ACTH concentrations which appeared maximal at 10 nM. CRH stimulated ACTH to a greater extent compared with DDAVP and potentiated the effect of DDAVP alone. The DDAVP-induced ACTH increase appeared blunted by vasopressin V2 and V3 receptor antagonists. V3 receptor gene expression was detected by RT-PCR in all adenoma samples except for two which were not responsive to DDAVP in vitro but responsive to the peptide in vivo. Surprisingly, no difference in the in vitro ACTH secretory response was observed between in vivo DDAVP-responsive (ACTH peak> 150% baseline) and -unresponsive (ACTH peak<120% baseline) patients, suggesting that the pituitary adenoma is not the sole mediator of the ACTH-releasing effect of DDAVP. In conclusion, the marked stimulatory effect of DDAVP observed in patients with Cushing's disease appears to be mainly dependent on an extrapituitary action, possibly the inhibition of a corticotrophin release-inhibitory factor.

UR - http://www.scopus.com/inward/record.url?scp=0038039453&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038039453&partnerID=8YFLogxK

U2 - 10.1677/joe.0.1770373

DO - 10.1677/joe.0.1770373

M3 - Article

C2 - 12773117

AN - SCOPUS:0038039453

VL - 177

SP - 373

EP - 379

JO - Journal of Endocrinology

JF - Journal of Endocrinology

SN - 0022-0795

IS - 3

ER -